AYTU BIOPHARMA, INC: 10-Q filed 2020-02-14

Name: AYTU BIOPHARMA, INC: 10-Q filed 2020-02-14
Creator: AYTU BIOPHARMA, INC

What AYTU BIOPHARMA, INC reported in its quarterly report filed 2020-02-14 (fiscal Q2 2020): 42 published measures, 109 facts as tagged in accession 0001654954-20-001622.

This filing

Form: 10-Q (quarterly report)
Filed: 2020-02-14
Fiscal period: fiscal Q2 2020
Accession: 0001654954-20-001622 on SEC EDGAR

Values are as tagged in this filing. A later filing can restate them; each measure links to its history page, which shows the latest-filed value per period. All AYTU BIOPHARMA, INC filings.

Reported measures

Total assets

Resources recognized on the balance sheet. Book assets are not the market value of the business.

Period	Value	Unit	Days
At 2019-12-31	74,477,635	USD
At 2019-06-30	34,721,391	USD

Total liabilities

Recognized obligations at the reporting date. The definition and scope differ from interest-bearing debt.

Period	Value	Unit	Days
At 2019-12-31	57,387,395	USD
At 2019-06-30	27,633,573	USD

Stockholders equity

The reported residual interest after liabilities. It is an accounting amount, not market capitalization.

Period	Value	Unit
At 2019-12-31	17,090,240	USD
At 2019-09-30	2,323,959	USD
At 2019-06-30	7,087,818	USD
At 2018-12-31	19,897,863	USD
At 2018-09-30	10,130,136	USD
At 2018-06-30	13,424,505	USD

Cash and cash equivalents

Cash and qualifying short-term liquid investments under the filer’s accounting policy. Restricted cash and longer-term investments may be reported separately.

Period	Value	Unit	Days
At 2019-12-31	5,259,492	USD
At 2019-06-30	11,044,227	USD

Net income or loss

Reported profit or loss for the period. Check the filing for attribution, exceptional items and discontinued operations before comparing companies.

Period	Value	Unit	Days
2019-10-01 to 2019-12-31	-214,247	USD	92
2019-07-01 to 2019-12-31	-5,143,277	USD	184
2019-07-01 to 2019-09-30	-4,929,030	USD	92
2018-10-01 to 2018-12-31	-4,657,662	USD	92
2018-07-01 to 2018-12-31	-8,104,145	USD	184
2018-07-01 to 2018-09-30	-3,446,483	USD	92

Operating cash flow

Cash generated or used by operating activities. Working-capital timing can make this differ substantially from reported income.

Period	Value	Unit	Days
2019-07-01 to 2019-12-31	-9,087,054	USD	184
2018-07-01 to 2018-12-31	-7,047,165	USD	184

Capital expenditure payments

Cash payments to acquire property, plant and equipment. This taxonomy concept does not capture every form of investment or acquisition.

Period	Value	Unit	Days
2019-07-01 to 2019-12-31	0	USD	184
2018-07-01 to 2018-12-31	12,954	USD	184

Revenue

Revenue under this specific accounting concept. A missing value is not zero; filers can use other revenue concepts.

Period	Value	Unit	Days
2019-10-01 to 2019-12-31	3,175,236	USD	92
2019-07-01 to 2019-12-31	4,615,062	USD	184
2018-10-01 to 2018-12-31	1,795,011	USD	92
2018-07-01 to 2018-12-31	3,226,820	USD	184

Financing cash flow

Net cash from financing activities, including borrowing, repayments and transactions with owners. A positive amount does not establish operating profitability.

Period	Value	Unit	Days
2019-07-01 to 2019-12-31	9,258,350	USD	184
2018-07-01 to 2018-12-31	18,700,037	USD	184

Investing cash flow

Net cash from investing activities, including asset purchases, disposals and investment transactions. This differs from capital expenditure payments alone.

Period	Value	Unit	Days
2019-07-01 to 2019-12-31	-5,954,635	USD	184
2018-07-01 to 2018-12-31	-860,287	USD	184

Retained earnings or deficit

Accumulated undistributed earnings or deficit at the reporting date. This balance is not cash available for distribution.

Period	Value	Unit	Days
At 2019-12-31	-111,532,777	USD
At 2019-06-30	-106,389,500	USD

Net property, plant and equipment

Carrying amount of property, plant and equipment after accumulated depreciation, depletion and amortization. It is not replacement cost or market value.

Period	Value	Unit	Days
At 2019-12-31	122,064	USD
At 2019-06-30	203,733	USD

Share-based compensation expense

Reported noncash expense for share-based payment arrangements. Noncash treatment does not mean the awards have no economic cost to shareholders.

Period	Value	Unit	Days
2019-07-01 to 2019-12-31	327,435	USD	184
2018-07-01 to 2018-12-31	346,176	USD	184

Operating income or loss

Operating revenue less operating expenses for the reporting period. It excludes items outside the reported operating result and is not free cash flow.

Period	Value	Unit	Days
2019-10-01 to 2019-12-31	-4,967,095	USD	92
2019-07-01 to 2019-12-31	-9,702,569	USD	184
2018-10-01 to 2018-12-31	-4,550,730	USD	92
2018-07-01 to 2018-12-31	-7,968,004	USD	184

Current assets

Assets classified as current under the normal operating cycle or one-year boundary. Not all current assets can be converted immediately into cash.

Period	Value	Unit	Days
At 2019-12-31	18,337,712	USD
At 2019-06-30	15,432,864	USD

Interest expense

Borrowing costs recognized as interest expense. This is distinct from cash interest paid and may not include every capitalized borrowing cost.

Period	Value	Unit	Days
2019-10-01 to 2019-12-31	446,958	USD	92
2019-07-01 to 2019-12-31	642,344	USD	184
2018-10-01 to 2018-12-31	127,569	USD	92
2018-07-01 to 2018-12-31	204,130	USD	184

Current liabilities

Obligations classified as current under the operating-cycle or one-year boundary. The balance includes more than short-term borrowing.

Period	Value	Unit	Days
At 2019-12-31	15,949,487	USD
At 2019-06-30	5,372,576	USD

Current accounts payable

Current amounts owed to suppliers for goods and services received. This is one component of current liabilities, not all accrued obligations.

Period	Value	Unit	Days
At 2019-12-31	9,598,567	USD
At 2019-06-30	2,297,270	USD

Goodwill carrying amount

Recognized goodwill remaining after accumulated impairment. It arises from business combinations and does not measure the current value of the company’s brand.

Period	Value	Unit	Days
At 2019-12-31	15,387,064	USD
At 2019-06-30	0	USD

Net finite-lived intangible assets

Finite-lived intangible assets after amortization. This excludes goodwill and should not be combined with indefinite-lived intangible assets without checking scope.

Period	Value	Unit	Days
At 2019-12-31	207,944	USD
At 2019-06-30	220,611	USD

Net current accounts receivable

Current customer receivables after the allowance for credit loss. The balance is not cash collected or a guarantee of collection.

Period	Value	Unit	Days
At 2019-12-31	5,197,151	USD
At 2019-06-30	1,740,787	USD

Operating expenses

Recurring operating costs under this accounting concept, generally excluding production costs included in cost of sales. Check filing presentation before combining expense subtotals.

Period	Value	Unit	Days
2019-10-01 to 2019-12-31	8,142,331	USD	92
2019-07-01 to 2019-12-31	14,317,631	USD	184
2018-10-01 to 2018-12-31	6,345,741	USD	92
2018-07-01 to 2018-12-31	11,194,824	USD	184

Net inventory

Inventory carrying amount after applicable valuation and LIFO reserves. It does not establish realizable selling proceeds or inventory turnover without other inputs.

Period	Value	Unit	Days
At 2019-12-31	2,491,807	USD
At 2019-06-30	1,440,069	USD

Cost of revenue

Costs attributed to goods produced and sold and services provided during the period. This is not the sum of every operating expense.

Period	Value	Unit	Days
2019-10-01 to 2019-12-31	606,046	USD	92
2019-07-01 to 2019-12-31	981,766	USD	184
2018-10-01 to 2018-12-31	525,138	USD	92
2018-07-01 to 2018-12-31	936,097	USD	184

Selling, general and administrative expense

Selling and general administrative costs reported under this concept. It is an expense category, not a substitute for total operating expenses.

Period	Value	Unit	Days
2019-10-01 to 2019-12-31	6,516,160	USD	92
2019-07-01 to 2019-12-31	11,662,603	USD	184
2018-10-01 to 2018-12-31	5,046,174	USD	92
2018-07-01 to 2018-12-31	8,622,754	USD	184

Research and development expense

Research and development costs recognized as expense. Capitalization policies and acquired projects can make this differ from total cash invested in development.

Period	Value	Unit	Days
2019-10-01 to 2019-12-31	66,675	USD	92
2019-07-01 to 2019-12-31	144,695	USD	184
2018-10-01 to 2018-12-31	149,029	USD	92
2018-07-01 to 2018-12-31	304,907	USD	184

Common shares outstanding

Common shares outstanding at the reporting date. This point-in-time count differs from the weighted-average shares used for earnings per share and can exclude other share classes.

Period	Value	Unit	Days
At 2019-12-31	20,733,052	shares
At 2019-06-30	17,538,071	shares

Additional paid-in capital

Capital contributed above par value under this concept. It records historical contributions, not the current value of the equity or cash on hand.

Period	Value	Unit	Days
At 2019-12-31	128,619,922	USD
At 2019-06-30	113,475,205	USD

Operating lease right-of-use asset

Carrying amount of the right to use leased assets under operating leases. It reflects discounted remaining payments, not the value of the underlying property.

Period	Value	Unit	Days
At 2019-12-31	374,568	USD
At 2019-06-30	0	USD

Operating lease liability

Present value of remaining operating lease payments. Discount-rate choices and lease terms affect the amount; it is not the sum of undiscounted future rent.

Period	Value	Unit	Days
At 2019-12-31	375,000	USD

Long-term debt

Long-term borrowings under this concept, which can include the current portion depending on presentation. It is not total liabilities and may exclude leases and other obligations.

Period	Value	Unit	Days
At 2019-12-31	23,394,761	USD
At 2019-06-30	0	USD

Accumulated depreciation on property, plant and equipment

Cumulative depreciation, depletion and amortization recorded against property, plant and equipment. It measures cost allocation to date, not physical wear or market value.

Period	Value	Unit	Days
At 2019-12-31	428,000	USD
At 2019-06-30	396,000	USD

Other noncurrent assets

Noncurrent assets the filer does not present separately. The composition differs by filer and is described only in the filing.

Period	Value	Unit	Days
At 2019-12-31	17,724,416	USD
At 2019-06-30	18,861,983	USD

Accrued current liabilities

Current obligations accrued for goods and services received but not yet invoiced or paid. This is one component of current liabilities, not all short-term obligations.

Period	Value	Unit	Days
At 2019-12-31	2,114,060	USD
At 2019-06-30	1,147,740	USD

Prepaid expenses and other current assets

Prepayments and other current assets grouped under this concept. The balance is not cash and its composition differs by filer.

Period	Value	Unit	Days
At 2019-12-31	2,361,249	USD
At 2019-06-30	957,781	USD

Profit or loss including noncontrolling interests

Net income or loss including the portion attributable to noncontrolling interests. It can differ from the net income attributable to the parent that per-share figures use.

Period	Value	Unit	Days
2019-07-01 to 2019-12-31	-5,143,277	USD	184
2018-07-01 to 2018-12-31	-8,104,145	USD	184

Depreciation, depletion and amortization

Combined depreciation, depletion and amortization for the period. A noncash allocation of asset cost, not a measure of maintenance spending.

Period	Value	Unit	Days
2019-07-01 to 2019-12-31	2,157,540	USD	184
2018-07-01 to 2018-12-31	1,230,671	USD	184

Amortization of intangible assets

Amortization recognized on finite-lived intangible assets. It follows acquisition accounting and does not indicate the intangibles are losing usefulness at that rate.

Period	Value	Unit	Days
2019-10-01 to 2019-12-31	953,450	USD	92
2019-07-01 to 2019-12-31	1,528,567	USD	184
2018-10-01 to 2018-12-31	534,063	USD	92
2018-07-01 to 2018-12-31	986,020	USD	184

Nonoperating income or expense

Total nonoperating income or expense, which can include interest, investment results and other items. A positive value is not operating profit.

Period	Value	Unit	Days
2019-10-01 to 2019-12-31	4,752,848	USD	92
2019-07-01 to 2019-12-31	4,559,292	USD	184
2018-10-01 to 2018-12-31	-106,932	USD	92
2018-07-01 to 2018-12-31	-136,141	USD	184

Interest paid, net

Cash interest paid during the period, net of amounts capitalized where the filer reports it that way. It differs from interest expense recognized.

Period	Value	Unit	Days
2019-07-01 to 2019-12-31	161,890	USD	184
2018-07-01 to 2018-12-31	0	USD	184

Change in accounts receivable

The cash flow adjustment for the change in receivables during the period. A positive value under this concept means receivables grew and reduced operating cash flow.

Period	Value	Unit	Days
2019-07-01 to 2019-12-31	3,456,364	USD	184
2018-07-01 to 2018-12-31	903,708	USD	184

Change in inventories

The cash flow adjustment for the change in inventories during the period. A positive value under this concept means inventory grew and reduced operating cash flow.

Period	Value	Unit	Days
2019-07-01 to 2019-12-31	132,199	USD	184
2018-07-01 to 2018-12-31	305,888	USD	184

Inspect the source

Entity: AYTU BIOPHARMA, INC / CIK 0001385818
Captured: 2026-09-20T07:58:53.461Z
SEC response SHA-256: 3b664ab8156647d48cbdda6c8eb0b5f1ac4147c50f45c9bb53fa74b58565a69b

Current SEC company facts · Download the original response snapshot (gzip) · Download the selected JSON

Every published concept a filing tagged, with the periods it covered, as reported in that filing at capture time. Forms 10-K, 10-K/A, 10-Q, 10-Q/A, 20-F, 20-F/A, 40-F, 40-F/A. A filing page needs at least 8 published concepts. Later filings can restate these values; the company history pages show the latest-filed value per period.

Public company accounting reference, not market prices, returns, an investment recommendation, or ALPHAC performance. Validate a separately constructed return series with the validation API; accounting values are not returns.

Use this in research

A financial period ends before its results become public. Use the filing date as a minimum availability boundary, inspect amendments, and retain the original filing vintage when testing historical signals. This latest-filed selection can contain information unavailable at the time.

These pages do not supply prices, total-return histories, corporate-action adjustments or a tradable universe. Build those inputs separately before evaluating a strategy. A profitable backtest can still reflect selection bias or costs that were left out.

Research methodology · Execution and cost assumptions · Check backtest overfitting

Build with the open-source tools

Use these accounting records as inspectable inputs. When you have constructed a return series, the validation tools can help test its statistical evidence and preserve the result with its limitations.

Read the published dataset with Python

import json
from urllib.request import urlopen

with urlopen("https://canlicapital.com/company-data/0001385818.json") as response:
    record = json.load(response)
print(record["fetched_at"])
print(record["policy"])
for concept in record["concepts"]:
    print(concept["tag"], next(iter(concept["observations"])))